Merck & Co., Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Merck & Co., Inc. (MRK) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $84.71 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-24
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $55.88, a 12.96% decline year-over-year.
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $64.20, a 31.48% increase year-over-year.
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $48.83, a 16.29% decline year-over-year.
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $58.33, a 6.27% increase year-over-year.
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $84.71, a 34.45% decline from fiscal 2024.
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $129.22, a 9.61% increase from fiscal 2023.
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $117.89, a 35.35% increase from fiscal 2022.
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $87.10, a 14.62% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $84.71 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $129.22 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $117.89 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $87.10 10-K · filed 2025-02-25 | |||
| 2021-12-31 | $75.99 10-K · filed 2024-02-26 | |||
| 2020-12-31 | $77.67 10-K · filed 2023-02-24 | |||
| 2020-09-30 | $77.67 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $77.67 10-Q · filed 2020-08-05 | |||
| 2019-12-31 | $80.05 10-K · filed 2022-02-25 | |||
| 2019-09-30 | $80.05 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $80.00 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $58.15 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $57.72 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $57.72 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $55.88 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $63.88 10-K · filed 2020-02-26 | |||
| 2017-09-30 | $63.96 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $63.98 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | $64.20 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | $54.63 10-K · filed 2019-02-27 | |||
| 2016-09-30 | $54.62 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $54.61 10-Q · filed 2017-08-08 | |||
| 2016-03-31 | $48.83 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $59.73 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $59.82 10-Q · filed 2016-11-07 | |||
| 2015-06-30 | $59.83 10-Q · filed 2016-08-08 | |||
| 2015-03-31 | $58.33 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | $58.14 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $58.15 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | $56.94 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | $54.89 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | $45.01 10-K · filed 2016-02-26 | |||
| 2013-09-30 | $45.00 10-Q · filed 2014-11-10 | |||
| 2013-06-30 | $44.98 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | $39.51 10-K · filed 2015-02-27 | |||
| 2012-09-30 | $39.39 10-Q · filed 2013-11-07 | |||
| 2012-06-30 | $39.26 10-Q · filed 2013-08-07 | |||
| 2012-03-31 | $38.63 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | $36.47 10-K · filed 2014-02-27 | |||
| 2011-09-30 | $36.55 10-Q · filed 2012-11-09 | |||
| 2011-06-30 | $36.55 10-Q · filed 2012-08-07 | |||
| 2010-12-31 | $34.30 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |